Monoclonal antibodies are used to block control points of the tumor development of many oncological pathologies. One of the critical control points of tumor development of several oncological pathologies is the receptor for programmed cell death (PD-1) and its ligands. Monoclonal antibodies against the PD-1 receptor are laboratory-derived humanized antibodies. An essential step in the humanization of antibodies is the production of murine hybrid cells producing monoclonal antibodies. This article describes studies of mice monoclonal antibodies against a recombinant human PD-1 receptor (rPD-1) expressed in Escherichia coli. To obtain strains of hybrid cells producing monoclonal antibodies, BALB/c mice were immunized with rPD-1 protein. B-lymphocytes of immunized mice were hybridized with the myeloma cell line of mice. Clones of hybrid cells were identified for productive activity and cloned by limiting dilution method. The properties of monoclonal antibodies were studied by enzyme-linked immunosorbent assay, Western blot and agar gel immunodiffusion. As a result, a hybrid cells producing monoclonal antibodies to a fragment of rPD-1 were obtained. Strains of hybrid cells have high productive activity in vitro and in vivo. Monoclonal antibodies react with rPD-1 protein, belong to the class of IgG1, and have a high binding constant. They efficiently bind to the PD-1 receptor and block the interaction of rPD-1 with the ligand. These monoclonal antibodies to rPD-1 can be used to obtain recombinant humanized monoclonal antibodies to the human PD-1 receptor.

• Adler AS, Mizrahi RA, Spindler MJ, Adams MS, Asensio MA, Edgar RC, Leong J, Leong R, Johnson DS (2017) Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade discovered using microfluidics and molecular genomics. MABS 9(8): 1270-1281. https://doi.org/10.1080/19420862.2017.1371386
• Alemayehu, Y., Adicha, A., Mengistu, M., & Eshetu, B. (2016). Assessments of Market Oriented Beef Cattle Fattening System Under Farmer Management Condition in South Omo Zone of Snnpr. Current Research in Agricultural Sciences, 3(3), 31-45.
• Beatty J, Beatty P, Vlahos W (1987) Measurement of monoclonal antibody affinity by non-competitive immunoassay. Journal of Immunological Methods 100(3): 173-179. https://doi.org/10.1016/0022-1759(87)90187-6
• Chen D, Tan S, Zhang H, Wang H, He W, Shi R, Tong Z, Zhu J, Cheng H, Gao S, Chai Y, Qi J, Xiao M, Yan J, Gao GF (2019) The FG loop of PD-1 serves as a “Hotspot” for therapeutic monoclonal antibodies in tumor immune checkpoint therapy. iScience 14: 113-124. https://doi.org/10.1016/j.isci.2019.03.017
• Coding JW (1980) Antibody production by hybridomas. Journal of Immunological Methods 39(4): 285-308. https://doi.org/10.1016/0022-1759(80)90230-6
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjoc T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Journal of Experimental Medicine 192: 1027-1034. https://doi.org/10.1084/jem.192.7.1027
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA (2010) Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 363(8): 711-723. https://doi.org/10.1056/NEJMoa1003466
• Khoja L, Butler MO, Kang SP, Ebbinghaus S Joshua AM (2015) Pembrolizumab. Journal for ImmunoTherapy of Cancer 3: 36. https://doi.org/10.1186/s40425-015-0078-9
• Kim CO, Amer A, Eszter LM, Yu Y, Xingxing Z (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine 21(1): 24-33. https://doi.org/10.1016/j.molmed.2014.10.009
• Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685. https://doi.org/10.1038/227680a0
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2: 261-268. https://doi.org/10.1038/85330
• Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256): 1734-1736. https://doi.org/10.1126/science.271.5256.1734
• Li K, Cheng X, Tilevik A, Davis SJ, Zhu C (2017) In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. Journal of Biological Chemistry 292(16): 6799-6809. https://doi.org/10.1074/jbc.M116.763888
• Liu H, Guo L, Zhang J, Zhou Y, Zhou J, Yao J, Wu H, Yao S, Chen B, Chai Y, Qi J, Gao GF, Tan S, Feng H, Yan J (2019) Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MABS 11: 681–690. https://doi.org/10.1080/19420862.2019.1596513
• Mamalis A, Garcha M, Jagdeo J (2014) Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Archives of Dermatological Research 306: 511-519. https://doi.org/10.1007/s00403-014-1457-7
• Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I (2016) Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. International Journal of Clinical Oncology 21: 456-461. https://doi.org/10.1007/s10147-016-0968-y
• Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery 9(10): 767-774. https://doi.org/10.1038/nrd3229
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical Cancer Research 13: 2151-2157. https://doi.org/10.1158/1078-0432.CCR-06-2746
• Oi VT, Herzenberg LA (1980) Immunoglobulin - producing hybrid cell lines. In: Selected methods in cellular immunology. Ed. Mishell BB and Shiigi SM pp. 351-352. San Francisco.
• Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M, Yoshimura A (2017) Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes antitumor immune responses of T cells. Cell Reports 20: 1017-1028. https://doi.org/10.1016/j.celrep.2017.07.027
• Ouchterlony O (1958) Diffusion - in gel methods for immunological analysis. Progress in Allergy 5: 1-78.
• Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 22: 252-264. https://doi.org/10.1038/nrc3239
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England Journal of Medicine 372(21): 2006-2017. https://doi.org/10.1056/NEJMoa1414428
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine 372(26): 2521-2532. https://doi.org/10.1056/NEJMoa1503093
• Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology 18(3): 153-167. https://doi.org/10.1038/nri.2017.108
• Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K (2016) Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investigational New Drugs 34: 347-354. https://doi.org/10.1007/s10637-016-0347-6
• Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ, Gao S, Wang Z, Shi Y, Yang F, Gao GF, Yan J (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications (8): 14369. https://doi.org/10.1038/ncomms14369
• Towbin PK, Strahelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proceeding National Academic Science USA 76: 4350-4354. https://doi.org/10.1073/pnas.76.9.4350
• Wang M, Wang J, Wang R, Jiao S, Wang S, Zhang J, Zhang M (2019) Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Communications Biology 2: 392. https://doi.org/10.1038/s42003-019-0642-9

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.